Literature DB >> 6430436

Effective treatment of Wilson's disease with oral zinc sulphate: two case reports.

T U Hoogenraad, C J Van den Hamer, J Van Hattum.   

Abstract

Most patients with Wilson's disease are treated with the potentially toxic cupriuretic agent penicillamine. The toxicity of zinc taken by mouth is low, and long term administration induces a negative copper balance. Two patients with severe neurological symptoms were given zinc sulphate by mouth three times daily in doses of 200 mg, later increased to 300 mg. One patient, a 21 year old man, started to receive zinc sulphate after his condition had deteriorated during treatment with cupriuretic drugs. The other, a 27 year old woman, was treated from the start with zinc sulphate. The conditions of both patients improved appreciably, and they were still receiving treatment with zinc sulphate roughly two years later. Effective depletion of body copper stores was shown by an intravenous radiocopper loading test and liver biopsy. No side effects were found. Wilson's disease may effectively be treated with zinc sulphate alone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430436      PMCID: PMC1442131          DOI: 10.1136/bmj.289.6440.273

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  12 in total

1.  Penicillamine, a new oral therapy for Wilson's disease.

Authors:  J M WALSHE
Journal:  Am J Med       Date:  1956-10       Impact factor: 4.965

2.  3 years of continuous oral zinc therapy in 4 patients with Wilson's disease.

Authors:  T U Hoogenraad; C J Van den Hamer
Journal:  Acta Neurol Scand       Date:  1983-06       Impact factor: 3.209

3.  [Tolerance of large doses of oral zinc sulfate].

Authors:  P Tschumi; G L Floersheim
Journal:  Schweiz Med Wochenschr       Date:  1981-10-17

4.  Possible errors in sampling percutaneous liver biopsies for determination of trace element status: application to patients with primary biliary cirrhosis.

Authors:  J L Nooijen; C J van den Hamer; J P Houtman; S W Schalm
Journal:  Clin Chim Acta       Date:  1981-07-01       Impact factor: 3.786

5.  Metabolic interactions of copper with other trace elements.

Authors:  C F Mills
Journal:  Ciba Found Symp       Date:  1980

6.  Sounding Boards. Historical controls: the practitioner's clinical trials.

Authors:  L Lasagna
Journal:  N Engl J Med       Date:  1982-11-18       Impact factor: 91.245

7.  Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.

Authors:  J M Walshe
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

8.  Hypocupremia induced by zinc therapy in adults.

Authors:  A S Prasad; G J Brewer; E B Schoomaker; P Rabbani
Journal:  JAMA       Date:  1978-11-10       Impact factor: 56.272

9.  Oral zinc therapy for Wilson's disease.

Authors:  G J Brewer; G M Hill; A S Prasad; Z T Cossack; P Rabbani
Journal:  Ann Intern Med       Date:  1983-09       Impact factor: 25.391

10.  Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration).

Authors:  T U Hoogenraad; R Koevoet; E G de Ruyter Korver
Journal:  Eur Neurol       Date:  1979       Impact factor: 1.710

View more
  4 in total

Review 1.  Current therapy of chronic liver disease.

Authors:  M W Stavinoha; R D Soloway
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Unithiol in Wilson's disease.

Authors:  T U Hoogenraad; J Van Hattum
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-20

3.  Oral zinc sulphate as primary therapeutic intervention in a child with Wilson disease.

Authors:  R Milanino; M Marrella; U Moretti; G P Velo; A Deganello; G Ribezzo; L Tatò
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

4.  Case report: concordant traumatic brainstem contusion delayed diagnosis in a young man with Wilson's disease.

Authors:  A Marcus; C Ammermann; M Klein; M H Schmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  1995-01       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.